biostudies-literatureUnknown3(1)Anagnostou E<h4>Unlabelled</h4><h4>Background</h4>There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.<h4>Methods</h4>This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intMolecular autism16https://www.ebi.ac.uk/biostudies/studies/S-EPMC3539865biostudies-literatureIntranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.PMC3539865Wang ATKushki AAnagnostou EChaplin WPepa LHollander ETanel NWasserman SSoorya LBartz JHalpern DfalseIntranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.<h4>Unlabelled</h4><h4>Background</h4>There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.<h4>Methods</h4>This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of int2012-01-01T00:00:00Z2012 Dec2026-07-15T08:41:00.102Z2026-07-02T03:11:50.628ZS-EPMC35398652321671610.1186/2040-2392-3-16